Literature DB >> 19529747

Neurological aspects of HIV/human T lymphotropic virus coinfection.

Marcus Tulius Silva1, Otávio de Melo Espíndola, Ana Cláudia C Bezerra Leite, Abelardo Araújo.   

Abstract

Human T lymphotropic virus type 1 is associated with some neurologic diseases, mainly human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Human T lymphotropic virus type 2 has also been associated with similar cases of human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis, but evidences for a definitive relationship are less clear. On the other hand, neurologic manifestations of HIV infection are quite common, affecting more than one third of patients in HIV clinics. Seroepidemiologic studies show that HIV-infected individuals are at an increased risk for human T lymphotropic virus infection and vice versa in comparison with the general population. Furthermore, HIV/human T lymphotropic virus coinfection has been associated with distinctive immunophenotypes and an increased risk for development of neurodegenerative conditions. Thus, studies on HIV/human T lymphotropic virus coinfection have a practice clinical importance. In this review, we aim to discuss clinical and laboratorial data focusing on neurologic diseases in HIV/human T lymphotropic virus coinfection.

Entities:  

Mesh:

Year:  2009        PMID: 19529747

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  11 in total

1.  Acute myelitis as presenting symptom of HIV-HTLV-1 co-infection.

Authors:  A Cucca; L Stragapede; L Antonutti; M Catalan; I Caracciolo; Romina Valentinotti; A Granato; P D'Agaro; P Manganotti
Journal:  J Neurovirol       Date:  2016-05-31       Impact factor: 2.643

Review 2.  HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status.

Authors:  Elisabetta Pilotti; Maria V Bianchi; Andrea De Maria; Federica Bozzano; Maria G Romanelli; Umberto Bertazzoni; Claudio Casoli
Journal:  Front Microbiol       Date:  2013-12-23       Impact factor: 5.640

Review 3.  Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review.

Authors:  Carolina Alvarez; Eduardo Gotuzzo; Anne-Mieke Vandamme; Kristien Verdonck
Journal:  Front Microbiol       Date:  2016-10-28       Impact factor: 5.640

4.  Modeling and analysis of a within-host HIV/HTLV-I co-infection.

Authors:  A M Elaiw; N H AlShamrani
Journal:  Bol Soc Mat Mex       Date:  2021-03-29

5.  Stability of an HTLV-HIV coinfection model with multiple delays and CTL-mediated immunity.

Authors:  N H AlShamrani
Journal:  Adv Differ Equ       Date:  2021-05-25

6.  CD4(+)CD25(High) Treg cells in HIV/HTLV co-infected patients with neuropathy: high expression of Alpha4 integrin and lower expression of Foxp3 transcription factor.

Authors:  Raquel Matavele Chissumba; Suse Dayse Silva-Barbosa; Ângelo Augusto; Cremildo Maueia; Nédio Mabunda; Eduardo Samo Gudo; Nilesh Bhatt; Ilesh Jani; Wilson Savino
Journal:  BMC Immunol       Date:  2015-09-02       Impact factor: 3.615

7.  Relative frequency of Human T-cell Lymphotropic Virus I/II in HIV/AIDS patients.

Authors:  Mohsen Meidani; Nooshin Ahmadi; Bahareh Jamali; Zahra Askarian
Journal:  Adv Biomed Res       Date:  2014-01-09

8.  The Effect of TAX-1 Gene of Human T-cell Leukemia Virus Type-1 on the Expression of CCR5 in K562 Cell Line.

Authors:  Nasrin Haghnazari Sadaghiani; Lila Pirayeshfard; Afsaneh Aghaie; Zohreh Sharifi
Journal:  Avicenna J Med Biotechnol       Date:  2019 Jan-Mar

Review 9.  Neurological Aspects of HIV-1/HTLV-1 and HIV-1/HTLV-2 Coinfection.

Authors:  Abelardo Q-C Araujo
Journal:  Pathogens       Date:  2020-03-28

10.  Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid and Accurate Confirmatory Diagnosis of HTLV-1/2 Infection.

Authors:  Yago Gomes; Adele Caterino-de-Araujo; Karoline Campos; Maria Gisele Gonçalves; Ana Claudia Leite; Marco Antonio Lima; Abelardo Araújo; Marcus Tulius Silva; Otávio Espíndola
Journal:  Viruses       Date:  2020-09-04       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.